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Background: Individuals with severe hemophilia A have reduced blood levels of clotting 
factor VIII (FVIII) leading to recurrent bleeding into joints and muscles. Primary prophylaxis 
with clotting factor concentrates started early in childhood prevents joint bleeds, thus avoiding 
joint damage and improving people’s quality of life. There remain significant differences in 
the implementation of primary prophylaxis worldwide mainly due to the cost of prophylaxis 
compared with treatment on demand.
Objective: To evaluate the cost-effectiveness of primary prophylaxis with FVIII concentrates 
versus secondary prophylaxis, versus treatment on demand, and versus a “hybrid” (primary 
prophylaxis followed by on-demand treatment in adults) in individuals with severe   
hemophilia A.
Methods: A Markov model was developed and run using different sources of clinical, cost, 
and utility data. The model was populated with a hypothetical cohort of 100 individuals with 
severe hemophilia A. The perspective of the Italian National Health System was used.
Results: The baseline results showed that primary and secondary prophylaxis is cost-effective 
compared both with treatment on demand and with a hybrid strategy. The incremental costs 
per quality-adjusted life-year gained for individuals with hemophilia A receiving primary and 
secondary prophylaxis were €40,229 to €40,236 versus an on-demand strategy. However, the 
sensitivity analyses performed showed that the results were sensitive to the unit cost of clotting 
FVIII, bleeding frequency, and the discount rate.
Conclusion: Although primary prophylaxis is a costly treatment, our results show that it is 
cost-effective compared with treatment on demand.
Keywords: hemophilia, cost-utility, factor VIII, prophylaxis, treatment on demand, 
quality of life
Introduction
Hemophilia A is a hereditary X-linked disorder caused by deficiency or absence of 
clotting factor VIII (FVIII) in the blood.1 The disease, which has an incidence of 1 in 
5000 to 10,000 male births,2 can be defined as mild, moderate, or severe depending on 
the degree of FVIII deficiency. Individuals with severe hemophilia A require lifelong 
treatment with exogenous FVIII to prevent bleeding and associated complications in 
muscles and joints,3 often leading to hemophilic arthropathy, a chronic painful and 
disabling condition with a considerable impact on their overall quality of life.4
Treatment with replacement therapy can be either on demand, when infusions of 
FVIII are given to treat a bleeding episode, or on prophylaxis when regular infusions of 
clotting concentrates are provided to prevent bleeding episodes. Moreover, prophylaxis 
is usually defined as primary when started before the age of 2 years and/or prior to ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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the first joint bleed and secondary when started after the 
age of 2 years and/or after more than 1 joint bleed. Primary 
prophylaxis is the gold standard treatment for children with 
severe hemophilia A. Despite this, there remain relevant 
differences in its implementation worldwide because of 
different healthcare priorities and available resources 
within the healthcare systems.1 In addition, the issue of 
when to stop prophylaxis is still open because few data on 
orthopedic outcome after a prolonged follow-up period are 
yet available.5 Recently published evidence6 has confirmed 
the long demonstrated benefits of prophylactic over 
on-demand therapy,1 though primary prophylaxis is more 
costly to provide.7 Considering the importance of prophylaxis 
in preventing joint damage and consequently in preserving 
hemophiliac patient’s quality of life, we have conducted 
an economic evaluation to assess the cost-effectiveness of 
prophylaxis with FVIII (recombinant plasma/albumin-free; 
ReFacto AF™, Pfizer) versus treatment on demand for 
individuals with severe hemophilia A.
Materials and methods
Our analysis is based on the study of Miners et al7 which 
evaluated the outcome of treating patients with severe 
hemophilia A with primary prophylaxis or on demand over a 
70-year time frame from the perspective of the UK National 
Health System.
To adapt Miners’ model to the Italian context, a few 
clinical parameters were varied and cost data were replaced 
with the corresponding Italian estimates of resource use.
The analysis conducted is a cost-utility analysis, ie, an 
economic evaluation that estimates the cost per quality-adjusted 
life-year (QALY) gained from undertaking one intervention 
instead of another.8 The QALY is a potential measure of 
health and is obtained by multiplying the duration of a health 
state (in years) by a factor representing the quality (“utility”) 
of that health state. A QALY value of 1 is equivalent to a 
year of “perfect health” whereas a value of zero corresponds 
to “death”.
The Markov model
In a Markov model a patient’s possible prognosis is divided 
into distinct health states. Costs and benefits are assigned to 
each health state and the movement of an individual between 
these health states over a given amount of time (cycle) is 
defined by transition probabilities.9,10 The costs and benefits 
of comparative treatments are then estimated according to 
the time spent in each state.
The model (Figure 1) was structured with the following 
assumptions:
•	 All individuals enter the model at birth in the health state 
“alive”.
•	 At the end of the first cycle (1 year) individuals either 
remain in the state “alive” or move to the health states 
“require major surgery” or “dead”.
•	 At the following cycle individuals in state “require major 
surgery” can pass to state “surgery” or “dead”.
•	 At the next cycle, individuals who underwent surgery 
move directly to state “alive” or “dead”.
Each cycle lasts 1 year and individuals end their treatment 
when they reach the age of 70 or are dead. Our model was 
run for a hypothetical cohort of 100 individuals and was 
re-run more times to simulate 4 different scenarios (Figure 2). 
Of note, scenario 2 was introduced purposely because it 
represents a “hybrid” program, that is, in this case, patients 
receive primary prophylaxis until the age of 18 years and 
subsequently switch to treatment on demand. Miners’ 
model7 was run using a combination of data obtained from 
different sources and was constructed on a few assumptions 
made by the authors, the majority of which were maintained 
in our model. However, a few adjustments on transition 
probabilities and costs were introduced to adapt the model 
to the Italian context. All input data used in the model 
are reported in Table 1. Modeling was undertaken using 
Microsoft Excel 2003 (Microsoft Corporation, Redmond, 
Washington, USA).
Transitions probabilities
Similarly with Miners’ analysis,7 it was assumed that life 
expectancy for individuals with severe hemophilia was 
equivalent to that of the general North European male 
population. Therefore, the probability of death in each 
year for individuals treated on demand and with primary 
Alive
Require major surgery
Dead
Surgery
Figure 1 structure of the model. The rectangles represent the possible disease 
states and the arrows indicate the possible transitions between those states.6ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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prophylaxis was based on a single Italian male life-table.11 
The probability of death in the year following major 
surgery was calculated based on the Italian male life-table 
mentioned above by adding an additional 1%, as explained 
elsewhere.7 The annual probability of requiring major surgery 
for individuals on primary prophylaxis was assumed to be 
equal to that of the Italian general population. The annual 
rate of major surgery was derived from the patients’ hospital 
discharge records; the mean annual probability of major 
surgery in individuals on primary prophylaxis was then 
calculated by considering data per single age category and 
found to be equal to 0.08% (mean value).12 For secondary 
prophylaxis and treatment on demand, the rates were based on 
Miners’ data7 but adjustments were made to take into account 
the increase of major surgery events with age.
Utilities
Because of the lack of suitable Italian data on the effect of 
the different treatment regimens on health-related quality of 
life of individuals with severe hemophilia A, the utilities for 
the health states “alive” and “surgery” imported to the model 
were derived from Miners et al.13 Similarly, the utility for 
the health state “require major surgery” was obtained from 
Laupacis et al14 who assumed that all individuals in that state 
suffered from a painful condition similar to that of individu-
als with osteoarthritis.
Age: 0–2 yrs
1
2**
3*
4
Scenario
Prophylaxis Prophylaxis On-demand
On-demand On-demand On-demand
Prophylaxis Prophylaxis Prophylaxis Primary
Prophylaxis
Prophylaxis Prophylaxis On-demand “Hybrid”
Secondary
prophylaxis
On demand
Age: > 19 yrs Age: 2–18 yrs
Figure 2 The four different scenarios simulated in the model.
Notes: *Regimen implemented in scandinavian countries (sweden) but not in italy; **introduced to represent a treatment strategy currently used in clinical practice in italy.
Table 1 input data used to run the italian model
  On demand Hybrid  
regimen
Primary  
prophylaxis
Secondary  
prophylaxis
References
start age (years) secondary prophyl. 2 *
End age (years) primary prophyl. 18 *
no. of patients treated 100 100 100 100 **
Discount rate 6.00% 6.00% 6.00% 6.00% 7
Annual probability of requiring  
major surgery 
2.30% 0.08%–2.30% 0.08% 0.70% 7; *; 7 
Dose  40 Ui kg 30–35 Ui kg 30 Ui kg 30 Ui kg 13; *; *
  Times per week 1.5 2.5 2.5 *; *; *
  no. of weeks Per bleeding 46 46 *; *; *
Utility = 1.03 (95% Ci 1.00 to 1.06) +	(-0.003 × age) 7
= 0.84 (95% Ci 0.74 to 0.94) +	(-0.006 (95% Ci -0.008 to -0.004) × age) 7
  Require major surgery 0.190 0.190 0.190 0.190 7
Bleeding frequency
  Adolescents 33.7 2.5–33.7 2.5 33.7–2.5 16
  Adults 36.9 5.4–36.9 5.4 36.9–5.4 16
Costs
  Recombinant plasma/albumin-free  
    ReFacto® (Pfizer) (IU)
€0.68 €0.68 €0.68 €0.68
hospitalizations for bleedings  
or examinations (unit cost)
€4,246 €4,246 €4,246 €4,246 4
hospitalizations for major  
surgery (unit cost)
€8,582 €8,582 €8,582 €8,582 4
Notes: *“Angelo Bonomi hemophilia and Thrombosis Center”, Milan, italy **Assumption.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Resource use
Clotting factor use
For treatment on demand it was considered that individuals 
with severe hemophilia A received a bolus dose of 40 IU/kg 
bodyweight once or twice after each bleed. In the case of 
secondary and primary prophylaxis the dosage was 30 IU/kg, 
to be administered 2.5 times per week.15
All costs associated with the administration of clotting 
FVIII were calculated considering the therapeutic regimens 
and the mean annual bleeding frequency, which were 
obtained from an Italian study by Tagliaferri et al.16 Data were 
entered into the model on the mean number of annual bleeds 
experienced by adolescents and adults treated on demand 
(33.7 and 36.9, respectively) and by adolescents and adults 
receiving prophylaxis (2.5 and 5.4 respectively). Additional 
resources taken into account were the unit costs associated 
with the hospitalizations for major surgery (€8582) and for 
bleeding or examinations (€4246).4
Cost analysis
The analysis was conducted from the perspective of the Italian 
National Health System (Sistema Sanitario Nazionale). 
A discount rate of 6% was applied to all costs as in Miners’ 
study7 and subsequently tested in the sensitivity analysis 
(Figures 3 to 5).
The unit costs for recombinant plasma/albumin-free 
antihemophilic factor (ReFacto AF) of €0.68 were obtained 
from the Italian Physicians’ Desk Reference (Informatore 
Farmaceutico 2010).17 Indirect costs were not taken into 
account in the analysis.
sensitivity analysis
One-way sensitivity analyses were performed varying the 
discount rate, the drug dose, and the administration frequency 
to test the robustness of the analysis.
Results
The results from the baseline analysis confirmed that the 
mean expected lifetime costs of treating individuals with 
severe hemophilia A are higher with primary prophylaxis 
(€166,168,643) than with treatment on demand (€87,426,642) 
when ReFacto AF was used (Table 2). In terms of effectiveness, 
however, primary and secondary phophylaxis are the most 
effective strategies as shown by the QALY values obtained: 
Primary prophyilaxis  vs On demand
0
25000
50000
75000
Start  Prophyl. second.18y
Stop  Prophyl. prim. 2y
Discount rate 3.5%
Prob. Major surgery +50%
Prob. Major surgery −50%
Dose FVIII +20%
Dose FVIII − 20%
Prophyl (3 weekly), On dem. (2 x bleed)
Prophyl (2 weekly), On dem. (1 x bleed)
Prophyl 52 ws
Bleed +20%
Bleed −20%
 Refacto FVIII
Figure 3 sensitivity analysis: primary prophylaxis versus treatment on demand.
Table 2 Total costs and incremental cost-effectiveness ratios (iCERs) for phrophylaxis vs treatment on demand in individuals with 
severe hemophilia A
  On demand Hybrid regimen Primary prophylaxis Secondary prophylaxis
Costs for 100 patients followed  
up for 70 ys
  Recombinant plasma/albumin-free  
    ReFacto® (Pfizer) (IU)
€87,426,642 €129,600,063 €166,168,643 €164,440,652
Effectiveness 4,137 4,491 6,094 6,051
  ICER (vs. on demand) 119,134 40,236 40,229ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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4137 for treatment on demand and 6094 and 6051 for primary 
and secondary prophylaxis, respectively, when ReFacto AF 
is considered (Table 2). If we analyze the QALYs in the four 
different scenarios, prophylaxis is always a cost-effective 
approach.
The hybrid scenario, in which individuals with severe 
hemophilia A initially receive prophylaxis and then switch 
to treatment on demand, is the least cost-effective, with 
incremental cost-effectiveness ratios (ICERs) of €119,134 
versus the on-demand strategy.
sensitivity analyses
The sensitivity analyses performed (Figures 3 to 5) show that 
results were sensitive to a number of variables   including the 
cost of the clotting factor, which is a cost driver in the model, 
the bleeding frequency, and the discount rate.
Discussion
The aim of this analysis was to conduct a cost-utility analysis 
of prophylaxis versus treatment on demand for individuals 
with severe hemophilia A in the Italian clinical setting. 
Hybrid vs On demand
0
25000
50000
75000
100000
125000
150000
Start  Prophyl. second.18y
Stop  Prophyl. prim. 5y
Discount rate 3.5%
Prob. Major surgery +50%
Prob. Major surgery −50%
Dose FVIII +20%
Dose FVIII −20%
Prophyl (3 weekly), On dem. (2 x bleed)
Prophyl (2 weekly), On dem. (1 x bleed)
Prophyl 52 ws
Bleed +20%
Bleed −20%
 Refacto FVIII
Figure 4 sensitivity analysis: hybrid regimen versus treatment on demand.
Secondary prophyilaxis  vs On demand
0
25000
50000
75000
Start  Prophyl. second.18y
Stop  Prophyl. prim. 5y
Discount rate 3.5%
Prob. Major surgery +50%
Prob. Major surgery −50%
Dose FVIII +20%
Dose FVIII −20%
Prophyl (3 weekly), On dem. (2 x bleed)
Prophyl (2 weekly), On dem. (1 x bleed)
Prophyl 52 ws
Bleed +20%
Bleed −20%
 Refacto FVIII
Figure 5 sensitivity analysis: secondary prophylaxis versus treatment on demand.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Though primary prophylaxis is recommended by national 
and international authorities such as the World Health 
Organization and the World Federation of Hemophilia,1 
many patients in different countries still receive treatment 
on demand. The importance of primary prophylaxis is due 
to the fact that it protects patients from the development of 
hemophilic arthropathy, and today there is strong agreement 
that to be effective, prophylaxis needs to be started at an 
early age, before arthropathy has developed.1 Nevertheless, 
implementation of prophylactic regimen is still hindered 
and one of the main arguments against its use is the cost of 
treatment.18
The results of our analysis show that prophylaxis is a 
cost-effective strategy compared with treatment on demand, as 
demonstrated by the QALY values obtained. This therapeutic 
strategy also dominates the hybrid regimen (as described in 
Methods), which has been considered in this analysis.
Our model has a number of limitations mainly due to its 
structure, the wide time horizon, the assumptions made, and 
the data used, some of which were derived from different 
sources. The fact that the possible indirect costs were not 
considered is another limitation, though their inclusion may 
have improved the results of the model. Clinical outcomes 
were derived from a literature review and were evaluated 
only for prophylaxis with recombinant plasma/albumin-free 
(ReFacto AF). Therefore, in a further economic evaluation it 
could be interesting to compare clinical effectiveness among 
different alternatives used in Italian setting; but data on costs 
and outcomes for different clotting factors would need to be 
collected over a longer period of time. Another important 
limitation is the assumptions on which the analysis was based, 
which may be necessary to simplify the model or in case of 
incomplete data. Specifically, this regarded the transition 
probabilities, which were lacking in some cases, and the 
utilities, which were derived from different literature sources 
and considered to be acceptable for an Italian population. To 
tackle the possible uncertainties associated with this way 
of proceeding we performed   one-way sensitivity analyses 
which highlighted that the results obtained were mainly 
sensitive to the discount rate used and the unit cost of the 
clotting factor.
To our knowledge, this is the first attempt to undertake a 
cost-utility analysis on hemophilia A considering prophylaxis 
versus treatment on demand in an Italian clinical setting. 
Though no officially established threshold on cost per QALY 
is available for Italy, our results show that the incremental 
costs per QALY gained for patients receiving primary and 
secondary prophylaxis were €40,236 to €40,229 versus the 
on-demand strategy. However, both ICERs were within the 
two commonly accepted thresholds of €36,500 per QALY19 
and €60,000 per QALY20 calculated by two different authors 
for the Italian setting. It is worth noting that recent guidelines 
by the Italian Health Economics Association recommend that 
a threshold of €25.000 to €40.000 be adopted.21
In spite of all the limitations of pharmacoeconomic 
models, these instruments have a key role when priorities in 
resource allocation have to be established. In fact, they pro-
vide decision-makers in the health care systems with useful 
tools to make more rational and effective decisions.
A more accurate estimate of the cost-effectiveness of 
prophylaxis may be obtained when appropriate data are 
collected. The randomized study ESPRIT (Evaluation Study 
on Prophylaxis: a Randomized Italian Trial),22 comparing the 
efficacy and safety of prophylaxis and on-demand regimens 
in preventing joint deterioration and reducing the number of 
bleeds, may provide meaningful evidence to be used in future 
prospective pharmacoeconomic evaluations.
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